This workflow automates the business intelligence layer of drug discovery, directly linking scientific progress to financial outcomes. It ingests data from ELNs, project management, and market intelligence systems—including development stage, probability of success (PoS) estimates, projected costs, and market size—to run Monte Carlo simulations. The system calculates the expected net present value (eNPV) and risk-adjusted return for each candidate and portfolio strategy, enabling R&D leadership to kill underperforming projects earlier and reallocate resources to maximize portfolio value.




